WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY
Herceptin administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens.
Evaluate left ventricular function in all patients prior to and during treatment with Herceptin. Discontinue Herceptin treatment in patients receiving adjuvant therapy and withhold Herceptin in patients with metastatic disease for clinically significant decrease in left ventricular function. [see Warnings and Precautions (5.1) and Dosage and Administration (2.2)]
Infusion Reactions; Pulmonary Toxicity
Herceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of Herceptin administration. Interrupt Herceptin infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue Herceptin for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. [see Warnings and Precautions (5.2, 5.4)
Embryo Fetal Toxicity
Exposure to Herceptin during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. [see Warnings and Precautions (5.3), Use in Specific Populations (8.1)]
Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product.
Adjuvant Breast Cancer
Herceptin is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies]) breast cancer
as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
with docetaxel and carboplatin
As a single agent following multi-modality anthracycline based therapy.
Metastatic Breast Cancer
Herceptin is indicated:
In combination with paclitaxel for first‑line treatment of HER2‑overexpressing metastatic breast cancer
As a single agent for treatment of HER2‑overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.
Media Articles Related to Herceptin (Trastuzumab)
Proposed biosimilar drug shows potential as breast cancer treatment
Source: Breast Cancer News From Medical News Today [2016.12.05]
Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with...
'Chemo Brain' Lasts for Months in Many Breast Cancer Survivors
Source: MedicineNet Depression Specialty [2017.01.12]
Title: 'Chemo Brain' Lasts for Months in Many Breast Cancer Survivors
Category: Health News
Created: 1/11/2017 12:00:00 AM
Last Editorial Review: 1/12/2017 12:00:00 AM
New insights into mechanisms of breast cancer development and resistance to therapy
Source: Breast Cancer News From Medical News Today [2017.01.11]
Why does breast cancer develop and how come certain patients are resistant to established therapies?
Obamacare Boosts Breast Cancer Screening, Study Finds
Source: MedicineNet Colon Cancer Specialty [2017.01.10]
Title: Obamacare Boosts Breast Cancer Screening, Study Finds
Category: Health News
Created: 1/9/2017 12:00:00 AM
Last Editorial Review: 1/10/2017 12:00:00 AM
'Overdiagnosis Exists in Breast Cancer'
Source: Medscape Hematology-Oncology Headlines [2017.01.09]
Another study provides evidence supporting the idea that breast cancer screening results in overdiagnosis of disease, and a new editorial provides historical perspective on how this came about.
Medscape Medical News
Published Studies Related to Herceptin (Trastuzumab)
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia
with human epidermal growth factor receptor 2-positive metastatic breast cancer:
results from the phase III trial CLEOPATRA. 
metastatic breast cancer... CONCLUSION: Despite a higher proportion of docetaxel dose reductions in patients
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with
trastuzumab and docetaxel for HER2-positive metastatic breast cancer. 
On June 8, 2012, the U.S. Food and Drug Administration (FDA) approved pertuzumab
(Perjeta, Genentech) for use in combination with trastuzumab (Herceptin,
Genentech) and docetaxel for the treatment of patients with HER2-positive
metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or
chemotherapy for metastatic disease...
Adjuvant trastuzumab in HER2-positive breast cancer. [2011.10.06]
BACKGROUND: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab... CONCLUSIONS: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. [2011.10]
AIM: To describe surgical outcomes in patients with HER2-positive locally advanced (LABC) or inflammatory breast cancer (IBC) participating in the NeOAdjuvant Herceptin (NOAH) study (ISRCTN86043495)... CONCLUSIONS: Although this was not an aim of the trial, neoadjuvant trastuzumab given concurrently with chemotherapy enabled 23% of patients with HER2-positive LABC/IBC to avoid mastectomy (including a small number of patients with IBC). Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. [2011.09.01]
PURPOSE: Trastuzumab is a humanized monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). The clinical benefits of adjuvant trastuzumab have been demonstrated in interim analyses of four large trials. Initial data of the combined analysis of the North Central Cancer Treatment Group (NCCTG) N9831 Intergroup trial and National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 trial were reported in 2005. Long-term follow-up results on disease-free survival (DFS) and overall survival (OS) have been awaited... CONCLUSION: These data demonstrate consistent DFS and OS advantages of adjuvant trastuzumab over time, with the longest follow-up reported to date. The clinical benefits continue to outweigh the risks of adverse effects.
Clinical Trials Related to Herceptin (Trastuzumab)
A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease [Completed]
This was a Phase II, randomized, multicenter, international, 2-arm, open-label clinical
trial designed to explore the efficacy and safety of trastuzumab emtansine (T-DM1) relative
to the combination of trastuzumab and docetaxel in patients with human epidermal growth
factor receptor 2 (HER2)-positive, unresectable, locally advanced breast cancer and/or
metastatic breast cancer who have not received prior chemotherapy for metastatic disease.
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer [Completed]
The purpose of this study is to determine if the combination of CPG 7909 and Herceptin is
safe and effective in the treatment of metastatic breast cancer.
RATIONALE: There is preclinical data that supports the hypothesis that CPG 7909 may
potentiate the action of Herceptin. This Phase I/II study is designed to evaluate the
safety and efficacy of the combination treatment of CPG 7909 and Herceptin in patients with
metastatic breast cancer who have previously been treated with Herceptin and chemotherapy.
SCHEDULE: Patients will receive CPG 7909 weekly for up to six months.
CPG 7909 Plus Herceptinï¿½ In Patients With Metastatic Breast Cancer [Completed]
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients
with metastatic breast cancer.
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer [Active, not recruiting]
The purpose of this study is to learn whether it is safe and effective to administer HKI-272
(neratinib) in combination with Herceptin in patients with advanced breast cancer.
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer [Completed]
This is an open-label Phase 1 trial of MM-111 in combination with Herceptin.
Reports of Suspected Herceptin (Trastuzumab) Side Effects
Disease Progression (83),
Febrile Neutropenia (63),
Dyspnoea (57), more >>
Page last updated: 2017-01-12